332382-81-7Relevant articles and documents
Design, synthesis and pharmacological evaluation of novel 2-chloro-3-(1: H -benzo [d] imidazol-2-yl)quinoline derivatives as antitumor agents: In vitro and in vivo antitumor activity, cell cycle arrest and apoptotic response
Kuang, Wen-Bin,Huang, Ri-Zhen,Fang, Yi-Lin,Liang, Gui-Bin,Yang, Chen-Hui,Ma, Xian-Li,Zhang, Ye
, p. 24376 - 24385 (2018)
A series of novel 2-chloro-3-(1H-benzo[d]imidazol-2-yl)quinoline derivatives (3a1-3d6) were designed and synthesized as antitumor agents. In vitro antitumor assay results showed that some compounds exhibited moderate to high inhibitory activities against HepG2, SK-OV-3, NCI-H460 and BEL-7404 tumor cell lines, and most compounds exhibited much lower cytotoxicities against HL-7702 normal cell line compared to 5-FU and cisplatin. In vivo antitumor assay results showed that the representative compound 3a1 exhibited effective inhibition on tumor growth in the HepG2 xenograft mouse model. Mechanistic studies suggested that 3a1 may exert antitumor activity by the up-regulation of Bax, intracellular Ca2+ release, ROS generation, p21, p27 and p53, downregulation of Bcl-2, activation of caspase-9 and caspase-3 and subsequent cleavage of PARP, and inhibition of CDK activity.
CHEMICAL ENTITIES, PHARMACEUTICAL FORMULATIONS, AND METHODS FOR TREATING FIBROSIS
-
, (2020/11/23)
Disclosed herein are chemical entities, or pharmaceutically acceptable salts thereof, for treating fibrosis, including pulmonary fibrosis, such as idiopathic pulmonary fibrosis. Also disclosed herein are pharmaceutical formulations for treating fibrosis, the pharmaceutical formulations including one or more of the foregoing chemical entities and one or more pharmaceutically acceptable excipients, carriers, vehicles, or a combination thereof. Also disclosed herein are packaged pharmaceutical formulations for treating fibrosis, the packaged pharmaceutical formulations including one of the foregoing pharmaceutical formulations and instructions for using the pharmaceutical formulation to treat a patient having fibrosis or susceptible to fibrosis. Also disclosed herein is a method for treating fibrosis, the method including administering one of the foregoing pharmaceutical formulations.
Design, synthesis and pharmacological evaluation of new 3-(1H-benzimidazol-2-yl)quinolin-2(1H)-one derivatives as potential antitumor agents
Kuang, Wen-Bin,Huang, Ri-Zhen,Qin, Jiao-Lan,Lu, Xing,Qin, Qi-Pin,Zou, Bi-Qun,Chen, Zhen-Feng,Liang, Hong,Zhang, Ye
, p. 139 - 150 (2018/08/09)
A series of new 3-(1H-benzimidazol-2-yl)quinolin-2(1H)-one derivatives (5a1?5d6) were designed and synthesized as antitumor agents. In vitro antitumor assay results showed that some compounds exhibited moderate to high inhibitory activity against HepG2, SK-OV-3, NCI-H460 and BEL-7404 tumor cell lines, and most compounds exhibited much lower cytotoxicity against the HL-7702 normal cell line compared to 5-FU and cisplatin. In vivo antitumor assay results demonstrated that 5a3 exhibited effective inhibition on tumor growth in the NCI-H460 xenograft mouse model and that 5d3 displayed excellent antiproliferative activity in the BEL-7402 xenograft model. These results suggested that both 5a3 and 5d3 could be used as anticancer drug candidates. Mechanistic studies suggested that compounds 5a3 and 5d3 exerted their antitumor activity by up-regulation of Bax, intracellular Ca2+ release, ROS generation, downregulation of Bcl-2, activation of caspase-9 and caspase-3 and subsequent cleavage of PARP, inhibition of CDK activity and activation of the p53 protein.
Synthesis and bio-evaluation of novel quinolino-stilbene derivatives as potential anticancer agents
Srivastava, Vandana,Lee, Hoyun
, p. 7629 - 7640 (2015/12/18)
A series of 25 novel quinolino-stilbene derivatives were designed, synthesized and evaluated for their potential as anticancer agents. Three of them not only displayed quite potent antiproliferative activity with IC50 values 50 values in the range of 4-10 μM, and the rest was moderately active or inactive. One of these viz. 3-[E-(4-fluorostyryl)]-2-chloroquinoline (compound 7B) caused substantial DNA damage and arrested cell cycle in S phase. Interestingly, 7B was very active against MDA-MB468 (IC50 = 0.12 μM), but not against other cell lines examined. Compound 3-[Z-(3-(trifluoromethyl)styryl)]-2-chloroquinoline (12A), the most effective against all cancer cell lines examined, caused prolonged cell cycle arrest at mitosis and eventually apoptosis. Data from an in vitro study showed that compound 12A inhibited microtubule polymerization in a similar fashion to nocodazole. Further study using in silico molecular modeling revealed that 12A causes the impediment of microtubule polymerization by binding to tubulin at the same cavity where podophyllotoxin binds.
Synthesis and biological evaluation of new rhodanine analogues bearing 2-chloroquinoline and benzo[h]quinoline scaffolds as anticancer agents
Ramesh, Vadla,Ananda Rao, Boddu,Sharma, Pankaj,Swarna,Thummuri, Dinesh,Srinivas, Kolupula,Naidu,Jayathirtha Rao, Vaidya
, p. 569 - 580 (2014/07/21)
Several rhodanine derivatives (9-39) were synthesized for evaluation of their potential as anticancer agents. Villsmeier cyclization to synthesize aza-aromatic aldehydes, rhodanine derivatives preparation and Knoevenagel type of condensation between the rhodanines and aza-aromatic aldehydes are key steps used for the synthesis of 31 compounds. In vitro antiproliferative activity of the synthesized rhodanine derivatives (9-39) was studied on a panel of six human tumor cell lines viz. HGC, MNK-74, MCF-7, MDAMB-231, DU-145 and PC-3 cell lines. Some of the compounds were capable of inhibiting the proliferation of cancer cell lines at a micromolar concentration. Six compounds are found to be potent against HGC cell lines; compound 15 is found to be active against HGC - Gastric, MCF7 - Breast Cancer and DU145 - Prostate Cancer cell lines; compound 39 is potent against MNK-74; four compounds are found to be potent against MCF-7 cell lines; three compounds are active against MDAMB-231; nine compounds are found to be potent against DU-145; three compounds are active against PC-3 cell lines. These compounds constitute a promising starting point for the development of novel and more potent anticancer agents in future.
Synthesis and biological evaluation of 10,11-methylenedioxy-14- azacamptothecin
Elban, Mark A.,Sun, Wenyue,Eisenhauer, Brian M.,Gao, Rong,Hecht, Sidney M.
, p. 3513 - 3516 (2007/10/03)
10,11-Methylenedioxy-14-azacamptothecin, a potent analogue of the antitumor agent camptothecin (CPT), has been prepared via a key condensation between AB and DE ring precursors. The biological testing of this compound validated a strategy for modulation of the off-rate of camptothecin analogues from the topoisomerase-DNA-CPT ternary complex via structural modification.
Efficient synthesis of 3-pyrrolylquinolines via an 1,3-dipolar cycloaddition/oxidation sequence
Menasra,Kedjadja,Debache,Rhouati,Belfaitah,Carboni, Bertrand
, p. 2779 - 2788 (2007/10/03)
The synthesis of some new functionalized quinolyl derivatives relies on the 1,3-dipolar cycloaddition of an azomethine ylide, generated from sarcosine and paraformaldehyde, to quinolyl α,β-unsaturated esters, followed by oxidation of the pyrrolidinyl moiety to pyrrole with activated MnO2. Copyright Taylor & Francis, Inc.
Homocamptothecins: Synthesis and antitumor activity of novel E-ring- modified camptothecin analogues
Lavergne, Olivier,Lesueur-Ginot, Laurence,Rodas, Francesc Pla,Kasprzyk, Philip G.,Pommier, Jacques,Demarquay, Danièle,Prévost, Grégoire,Ulibarri, Gérard,Rolland, Alain,Schiano-Liberatore, Anne-Marie,Harnett, Jeremiah,Pons, Dominique,Camara, José,Bigg, Dennis C. H.
, p. 5410 - 5419 (2007/10/03)
Homocamptothecin (hCPT), a camptothecin (CPT) analogue with a seven membered β-hydroxylactone which combines enhanced plasma stability and potent topoisomerase I (Topo I) mediated activity, is an attractive template for the elaboration of new anticancer a
